[1]
Tanner L, Müller MM. [Blood Transfusion: a Guide to Clinical Decision Making]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS. 2019 Mar:54(3):194-205. doi: 10.1055/a-0593-4390. Epub 2019 Mar 13
[PubMed PMID: 30866023]
[2]
Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Research and practice in thrombosis and haemostasis. 2019 Jan:3(1):26-37. doi: 10.1002/rth2.12160. Epub 2018 Nov 16
[PubMed PMID: 30656273]
[3]
Wiernek SL, Jiang B, Gustafson GM, Dai X. Cardiac implications of thrombotic thrombocytopenic purpura. World journal of cardiology. 2018 Dec 26:10(12):254-266. doi: 10.4330/wjc.v10.i12.254. Epub
[PubMed PMID: 30622684]
[4]
Cox EC. Thrombotic thrombocytopenic purpura: report of three additional cases and a short review of the literature. Journal of the South Carolina Medical Association (1975). 1966 Dec:62(12):465-70
[PubMed PMID: 5232420]
Level 3 (low-level) evidence
[5]
Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. The New England journal of medicine. 1991 Aug 8:325(6):398-403
[PubMed PMID: 2062331]
[6]
Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Frontiers in immunology. 2019:10():337. doi: 10.3389/fimmu.2019.00337. Epub 2019 Feb 27
[PubMed PMID: 30891033]
[7]
Amin Asnafi A, Jalali MT, Pezeshki SMS, Jaseb K, Saki N. The Association Between Human Leukocyte Antigens and ITP, TTP, and HIT. Journal of pediatric hematology/oncology. 2019 Mar:41(2):81-86. doi: 10.1097/MPH.0000000000001381. Epub
[PubMed PMID: 30543580]
[8]
van Dorland HA, Taleghani MM, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, Vesely SK, Matsumoto M, Lämmle B, Fujimura Y, Kremer Hovinga JA, Hereditary TTP Registry. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019 Oct:104(10):2107-2115. doi: 10.3324/haematol.2019.216796. Epub 2019 Feb 21
[PubMed PMID: 30792199]
[9]
Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. Journal of clinical apheresis. 2019 Feb:34(1):44-50. doi: 10.1002/jca.21673. Epub 2018 Dec 8
[PubMed PMID: 30536422]
[10]
Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. American journal of hematology. 2010 Nov:85(11):844-7. doi: 10.1002/ajh.21833. Epub
[PubMed PMID: 20799358]
[11]
Shelat SG, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Seminars in thrombosis and hemostasis. 2005 Dec:31(6):659-72
[PubMed PMID: 16388417]
[12]
Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Current opinion in hematology. 2015 Sep:22(5):452-9. doi: 10.1097/MOH.0000000000000169. Epub
[PubMed PMID: 26186678]
Level 3 (low-level) evidence
[13]
Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology. American Society of Hematology. Education Program. 2018 Nov 30:2018(1):530-538. doi: 10.1182/asheducation-2018.1.530. Epub
[PubMed PMID: 30504354]
[14]
Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology. American Society of Hematology. Education Program. 2018 Nov 30:2018(1):539-547. doi: 10.1182/asheducation-2018.1.539. Epub
[PubMed PMID: 30504355]
[15]
George JN, Nester CM. Syndromes of thrombotic microangiopathy. The New England journal of medicine. 2014 Aug 14:371(7):654-66. doi: 10.1056/NEJMra1312353. Epub
[PubMed PMID: 25119611]
[16]
George JN. Clinical practice. Thrombotic thrombocytopenic purpura. The New England journal of medicine. 2006 May 4:354(18):1927-35
[PubMed PMID: 16672704]
[17]
George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park, N.Y.). 2011 Sep:25(10):908-14
[PubMed PMID: 22010388]
[18]
Ruggenenti P, Remuzzi G. Pathophysiology and management of thrombotic microangiopathies. Journal of nephrology. 1998 Nov-Dec:11(6):300-10
[PubMed PMID: 10048496]
[19]
Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR, Ballard RB, Terrell DR, Vesely SK, George JN, Marques MB. First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? Transfusion. 2013 Jan:53(1):235-7. doi: 10.1111/j.1537-2995.2012.03934.x. Epub
[PubMed PMID: 23294213]
[20]
Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. European journal of haematology. 2014 Feb:92(2):156-63. doi: 10.1111/ejh.12222. Epub 2013 Nov 26
[PubMed PMID: 24164539]
[21]
Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F, Mira JP, Wynckel A, Presne C, Poullin P, Halimi JM, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Cohen A, Veyradier A, Coppo P, Reference Center for Thrombotic Microangiopathies. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. Journal of thrombosis and haemostasis : JTH. 2015 Feb:13(2):293-302. doi: 10.1111/jth.12790. Epub 2014 Dec 18
[PubMed PMID: 25403270]
[22]
Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood advances. 2017 Apr 11:1(10):590-600. doi: 10.1182/bloodadvances.2017005124. Epub 2017 Apr 6
[PubMed PMID: 29296701]
Level 3 (low-level) evidence
[23]
Plautz WE, Raval JS, Dyer MR, Rollins-Raval MA, Zuckerbraun BS, Neal MD. ADAMTS13: origins, applications, and prospects. Transfusion. 2018 Oct:58(10):2453-2462. doi: 10.1111/trf.14804. Epub 2018 Sep 12
[PubMed PMID: 30208220]
[24]
Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thrombosis journal. 2018:16():20. doi: 10.1186/s12959-018-0174-4. Epub 2018 Aug 11
[PubMed PMID: 30127669]
[25]
Jia X, He Y, Ruan CG. [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review]. Zhongguo shi yan xue ye xue za zhi. 2018 Aug:26(4):1230-1234. doi: 10.7534/j.issn.1009-2137.2018.04.048. Epub
[PubMed PMID: 30111436]
Level 3 (low-level) evidence
[26]
Jamme M, Rondeau E. The PLASMIC score for thrombotic thrombocytopenic purpura. The Lancet. Haematology. 2017 Apr:4(4):e148-e149. doi: 10.1016/S2352-3026(17)30024-8. Epub 2017 Mar 2
[PubMed PMID: 28259521]
[27]
Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis. Transfusion. 2020 Sep:60(9):2047-2057. doi: 10.1111/trf.15954. Epub 2020 Aug 5
[PubMed PMID: 32757237]
Level 1 (high-level) evidence
[28]
Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Böhm M, Plaimauer B, Lämmle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005 Aug 15:106(4):1262-7
[PubMed PMID: 15890682]
[29]
Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis : JTH. 2020 Oct:18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11
[PubMed PMID: 32914526]
[30]
Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. American journal of hematology. 1990 Jul:34(3):169-74
[PubMed PMID: 2363411]
[31]
Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton, Vic.). 2018 Jun:23(6):507-517. doi: 10.1111/nep.13234. Epub
[PubMed PMID: 29419916]
Level 3 (low-level) evidence
[32]
Matsumoto M. [New developments in treatment modalities of thrombotic thrombocytopenic purpura]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2017:58(10):2081-2086. doi: 10.11406/rinketsu.58.2081. Epub
[PubMed PMID: 28978852]
[33]
Miyakawa Y. [TTP and aHUS: new insights]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2017:58(5):530-536. doi: 10.11406/rinketsu.58.530. Epub
[PubMed PMID: 28592771]
[34]
Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec:52(12):2525-32; quiz 2524. doi: 10.1111/j.1537-2995.2012.03646.x. Epub 2012 Apr 15
[PubMed PMID: 22501034]
[35]
Cilla N, Dallemagne J, Vanhove M, Stordeur P, Motte S, De Wilde V. Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab. Journal of hematology. 2020 Sep:9(3):84-88. doi: 10.14740/jh614. Epub 2020 Aug 14
[PubMed PMID: 32855757]
[36]
Siddiqui A, Journeycake JM, Borogovac A, George JN. Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatric blood & cancer. 2021 May:68(5):e28949. doi: 10.1002/pbc.28949. Epub 2021 Mar 4
[PubMed PMID: 33660913]
[37]
Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? British journal of haematology. 1994 Jun:87(2):317-20
[PubMed PMID: 7947273]
[38]
Matsumoto M. [Consensus report on the diagnosis and management of thrombotic thrombocytopenic purpura 2017]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2017:58(4):271-281. doi: 10.11406/rinketsu.58.271. Epub
[PubMed PMID: 28484152]
Level 3 (low-level) evidence
[39]
Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology. American Society of Hematology. Education Program. 2014 Dec 5:2014(1):444-9. doi: 10.1182/asheducation-2014.1.444. Epub 2014 Nov 18
[PubMed PMID: 25696892]
[40]
Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016:10():649. doi: 10.3332/ecancer.2016.649. Epub 2016 Jun 28
[PubMed PMID: 27433282]
[41]
Pannu AK, Saroch A. Thrombotic Thrombocytopenic Purpura or Disseminated Intravascular Coagulation? Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2017 Aug:21(8):539. doi: 10.4103/ijccm.IJCCM_174_17. Epub
[PubMed PMID: 28904488]
[42]
Vincent JL, Castro P, Hunt BJ, Jörres A, Praga M, Rojas-Suarez J, Watanabe E. Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies-what intensivists need to know. Critical care (London, England). 2018 Jun 13:22(1):158. doi: 10.1186/s13054-018-2073-2. Epub 2018 Jun 13
[PubMed PMID: 29895296]
[43]
Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. Journal of blood medicine. 2016:7():181-6. doi: 10.2147/JBM.S102235. Epub 2016 Sep 2
[PubMed PMID: 27621680]
[44]
Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Deutsches Arzteblatt international. 2018 May 11:115(19):327-334. doi: 10.3238/arztebl.2018.0327. Epub
[PubMed PMID: 29875054]
[45]
Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. American journal of hematology. 2011 Sep:86(9):743-51. doi: 10.1002/ajh.22091. Epub
[PubMed PMID: 21850657]
[46]
Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Current opinion in hematology. 2001 Sep:8(5):286-93
[PubMed PMID: 11604563]
Level 3 (low-level) evidence
[47]
Manor SM, Guillory GS, Jain SP. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy. 2004 May:24(5):664-7
[PubMed PMID: 15162901]
[48]
Azarm T, Sohrabi A, Mohajer H, Azarm A. Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2011 Mar:16(3):353-7
[PubMed PMID: 22091257]
Level 3 (low-level) evidence
[49]
Khodor S, Castro M, McNamara C, Chaulagain CP. Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. Hematology/oncology and stem cell therapy. 2016 Jun:9(2):76-9. doi: 10.1016/j.hemonc.2015.11.003. Epub 2015 Dec 2
[PubMed PMID: 26684918]
[50]
Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A, Nine-i Investigators. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive care medicine. 2019 Nov:45(11):1518-1539. doi: 10.1007/s00134-019-05736-5. Epub 2019 Oct 7
[PubMed PMID: 31588978]
[51]
Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006 Oct:46(10):1693-704
[PubMed PMID: 17002625]
Level 1 (high-level) evidence
[52]
Trachtman H. HUS and TTP in Children. Pediatric clinics of North America. 2013 Dec:60(6):1513-26. doi: 10.1016/j.pcl.2013.08.007. Epub
[PubMed PMID: 24237985]
[53]
Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Etiology and Outcomes of Thrombotic Microangiopathies. Clinical journal of the American Society of Nephrology : CJASN. 2019 Apr 5:14(4):557-566. doi: 10.2215/CJN.11470918. Epub 2019 Mar 12
[PubMed PMID: 30862697]
[54]
George JN. TTP: long-term outcomes following recovery. Hematology. American Society of Hematology. Education Program. 2018 Nov 30:2018(1):548-552. doi: 10.1182/asheducation-2018.1.548. Epub
[PubMed PMID: 30504356]